# Accutar Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accutar-biotechnology

- Industry: Biotechnology
- Headquarters: Brooklyn, US
- Website: www.accutarbio.com
- Latest round: Series A (Dec 5, 2017)
- Investors on record: 3

## About

Accutar Biotechnology Inc., based in the US, is a biopharmaceutical company focused on developing targeted therapies for oncology and other serious diseases through innovative technology solutions.Founded in 2015 in Brooklyn, US, Accutar Biotechnology Inc. specializes in the development of biopharmaceuticals aimed at addressing specific genetic mutations in cancer. The company has completed 5 deals, with its most recent funding round occurring on 7 April 2021. Jie Fan, who has a background in various biotechnology ventures, serves as CEO and founder of the company. Accutar has raised a total of USD 28.00 mn through its funding rounds.Accutar Biotech specializes in innovative biopharmaceutical solutions, focusing on the development and commercialization of targeted therapies aimed at oncology and other serious diseases. The company’s core product offerings include a suite of novel drug candidates designed to address specific genetic mutations in cancer cells, enhancing treatment efficacy while minimizing side effects. These therapies leverage cutting-edge technologies such as artificial intelligence and machine learning to optimize drug discovery and development processes. Its primary customer base comprises healthcare institutions, research organizations, and pharmaceutical partners across North America, Europe, and Asia-Pacific regions. By targeting unmet medical needs, Accutar Biotech aims to improve patient outcomes and provide solutions for oncologists and healthcare providers dealing with complex cancer cases.Accutar Biotech generates revenue through strategic partnerships and collaborations with leading healthcare organizations and pharmaceutical companies. The company engages in B2B transactions, entering into agreements that may include milestone payments tied to the successful development of its drug candidates. Given its focus on oncology, transactions are likely structured around significant research and development agreements, in which Accutar provides access to its proprietary technologies in exchange for upfront fees and royalties on future product sales. Accutar’s flagship products are expected to command premium pricing due to their targeted approach and therapeutic value, positioning the company favorably within the competitive biopharmaceutical landscape. The revenue model is designed to foster long-term relationships with partners while advancing its pipeline of therapeutic candidates.Accutar Biotechnology Inc. intends to leverage the recent funding of USD 28.00 mn raised in April 2021 from new investors YF Capital, Coatue Management, and 3W Fund Management to support the development of new targeted therapies and expand its market presence. The company is focused on launching additional drug candidates designed to address specific genetic mutations in cancer by 2023. Additionally, Accutar aims to penetrate new markets in Europe and Asia-Pacific by the end of 2023, enhancing its global footprint in the biopharmaceutical sector.

## Funding rounds

- Series A, Dec 5, 2017 — IDG Capital, Shanghai Yitu Technology Co., Ltd.
- Angel, Dec 30, 2016 — ZhenFund

## Investors

- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Angel
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A
- Shanghai Yitu Technology Co., Ltd. — Series A